( Chief Scientist to Present Results at 2...)Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study,Health

CLEVELAND, April 09, 2007 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. , announced today the results of its study of Protectan CBLB502's efficacy as a mitigator of both gastrointestinal (GI) and hematopoietic (bone marrow/blood production) radiation-induced damage in non-human primates. The Company's Chief Scientific Officer, Andrei Gudkov, Ph.D, D. Sci., will present results of the study at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18, in Los Angeles, CA.

In the study, Rhesus monkeys were irradiated with 6.5 Gy of total body irradiation and injected intramuscularly with either a single dose of Protectan CBLB502 or a placebo, one hour after irradiation. No supportive therapy was applied. The animals were observed for 40 days. CBLB502 enabled survival of 70% of the animals in the protected group, versus the control group, in which 20% of the animals survived. In addition, gross pathology results showed that the majority of control animals displayed severe damage to the GI tract, while the CBLB502 treated animals did not. This data demonstrates CBLB502's capacity as a mitigator of gastrointestinal radiation-induced injury.

Dr. Gudkov commented, "The level of protection observed in this study is very impressive and we are gratified to see that it is as high as the level achieved when Protectan CBLB502 is administrated one hour prior to irradiation. This confirms our previously achieved results in mitigation of radiation damage in rodents. CBLB502 is the first compound to provide protection from both gastrointestinal and hematopoietic radiation-induced damage when administrated before or after irradiation. Moreover, mitigation shown in two animal species opens much broader potential markets for CBLB502's use as a radiation antidote."

The Company is subm
'"/>